Mathilde Marchand

6PUBLICATIONS
26CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 31, 2026
Refinement of Operating Characteristics for Model-Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology.

|Feb 05, 2025
Population Pharmacokinetics and Exposure-Response of Subcutaneous Atezolizumab in Patients With Non-Small Cell Lung Cancer.

Phyllis Chan, Stephanie N Liu, Nathalie Gosselin

|May 29, 2024
Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma.

Brendan Bender, Chi-Chung Li, Mathilde Marchand

|Apr 17, 2024
Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two-stage approaches.

Mathilde Marchand, Antonio Gonçalves, François Mercier

|Oct 25, 2023
Comparison of two-stage and joint TGI-OS modeling using data from six atezolizumab clinical studies in patients with metastatic non-small cell lung cancer.

Antonio Gonçalves, Mathilde Marchand, Phyllis Chan

|Jan 03, 2023
Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.

René Bruno, Mathilde Marchand, Kenta Yoshida

Pageof 1

Frequent Collaborators

5 joint publications

Pascal Chanu

5 joint publications

Jin Y Jin

4 joint publications

René Bruno

3 joint publications

Phyllis Chan